|
|
|
|
|
|
Companies > Commercial
|
|
|
Nervomatrix developed and commercialized an FDA approved technology that combines the action of mapping peripheral nerve endings associated with pain and providing intense electrical stimulation at these points. Following the early market entry and with an excellent practitioners and patients feedback, the company expects it's evidence based superior technology to bring about effective solution to huge market in great need.
Funders:
Everett Partners, Startvest, Targetech
|
|
|
|
|